| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20004694 | HPV | ENSG00000181143.17 | protein_coding | MUC16 | No | No | 94025 | Q8WXI7 |
| TVIS20005951 | HPV | ENSG00000181143.17 | protein_coding | MUC16 | No | No | 94025 | Q8WXI7 |
| TVIS20010500 | HPV | ENSG00000181143.17 | protein_coding | MUC16 | No | No | 94025 | Q8WXI7 |
| TVIS20045451 | HPV | ENSG00000181143.17 | protein_coding | MUC16 | No | No | 94025 | Q8WXI7 |
| TVIS20030941 | HPV | ENSG00000181143.17 | protein_coding | MUC16 | No | No | 94025 | Q8WXI7 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | MUC16 |
|---|---|
| DrugBank ID | DB04964 |
| Drug Name | Oregovomab |
| Target ID | BE0002439 |
| UniProt ID | Q8WXI7 |
| Regulation Type | |
| PubMed IDs | 15268682; 17073521 |
| Citations | Berek JS: Immunotherapy of ovarian cancer with antibodies: a focus on oregovomab. Expert Opin Biol Ther. 2004 Jul;4(7):1159-65.@@Authors unspecified: Oregovomab: anti-CA-125 monoclonal antibody B43.13--AltaRex, B43.13, MAb B43.13, monoclonal antibody B43.13. Drugs R D. 2006;7(6):379-83. |
| Groups | Investigational |
| Direct Classification | Peptides |
| SMILES | |
| Pathways | |
| PharmGKB | |
| ChEMBL |
